Pain Therapeutics

Beiträge: 32
Zugriffe: 5.608 / Heute: 2
Pain Therapeutics kein aktueller Kurs verfügbar
 
Pain Therapeutics mehrmeer
mehrmeer:

News

 
05.10.18 09:21
#26
werden auch bei I-Hub im Breakout Board angezeigt.Momentan auf Platz 4.Könnte helfen,die Amis stehen
auf Low Floater.-
investorshub.advfn.com/boards/breakoutboards.aspx
Pain Therapeutics Frozenfrog
Frozenfrog:

Hoffen wir

 
05.10.18 09:22
#27
Mal. Das gestern war schon krass. Nur weil man mehr erwartet hat. Tsts
Pain Therapeutics Vassago
Vassago:

PTIE 0,80$

 
24.12.18 17:25
#28
MK 14 Mio. $ < Cash 20 Mio. $
Pain Therapeutics Vassago
Vassago:

PTIE 1,05$ (-13%)

 
05.02.19 16:50
#29
MK 18 Mio. $

investor.paintrials.com/news-releases/...nt-meeting-fda-remoxy
Pain Therapeutics Balu4u
Balu4u:

...

 
26.02.19 13:03
#30
seekingalpha.com/news/...ealth-pain-therapeutics-among-losers

Noch Leben drin? Gestern zumindest mal 9 Prozent hoch!
Pain Therapeutics Vassago
Vassago:

PTIE 1,14$

 
26.03.19 10:59
#31

Operating Highlights for 2018 and Forecast for 2019--

  • Historically, our lead drug candidate had been REMOXY, which is the trade name for an abuse-deterrent, extended-release form of oxycodone to treat severe chronic pain. The U.S. Food and Drug Administration (FDA) has previously found REMOXY to be an effective analgesic drug for the treatment of severe chronic pain. However, FDA has not approved REMOXY on the basis that additional demonstrations of its abuse deterrent properties are needed, a matter of dispute between us and FDA.


  •    On March 20, 2019, we provided Durect Corporation with written notice of termination of a Development and License Agreement (DLA). Termination of the DLA effectively ends our clinical development of REMOXY.
  • In October 2018, we announced a strategic reorganization to align Company resources on advancing our programs in neurodegenerative diseases, such as Alzheimer’s disease.
       
      --- In December 2018, we announced the initiation of a Phase II study to evaluate PTI-125 in patients with Alzheimer’s disease. This clinical study is supported by a research grant award from the National Institute on Aging of the NIH, the primary Federal agency supporting innovative new research in Alzheimer’s disease.

  • In 2019, we expect to rebrand the Company around neurodegeneration. Our rebranding plans include a new company name, logo, ticker symbol, website, as well as a comprehensive strategy to bolster media outreach and an active approach to engage with potential new shareholders.

investor.paintrials.com/news-releases/...results-and-corporate

Pain Therapeutics Vassago

Namensänderung

 
#32
Pain Therapeutics heißt jetzt Cassava Sciences (SAVA)

seekingalpha.com/news/...in-therapeutics-now-cassava-sciences

Seite: Übersicht 1 2 ZurückZurück

Hot-Stocks-Forum - Gesamtforum - Antwort einfügen - zum ersten Beitrag springen

Neueste Beiträge aus dem Pain Therapeutics Forum

  
Wertung Antworten Thema Verfasser letzter Verfasser letzter Beitrag
  31 Pain Therapeutics Kurios1 Vassago 28.03.19 16:34

--button_text--